Cassava: Alzheimer Treatment’s Progress Merits a New Price Target
The development of Cassava Sciences’ (SAVA) Alzheimer treatment
appears to be rolling along smoothly. On Monday, the biotech said
its End-of Phase 2 (EOP2) mid-January meeting with the FDA had gone
well. The company met up with the regulatory body to discuss the
path forward for simufilam, Cassava’s Alzheimer’s disease (AD) drug
candidate, which is now ready for a Phase 3 trial. After speaking
with management, H.C.